^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    finotonlimab (SCT-I10A)

    i
    Associations
    News

    Trials

    Company:
    Sinocelltech
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT05552807)
    Phase 1
    Sinocelltech Ltd.
    Recruiting
    Last update posted :
    09/23/2022
    Initiation :
    06/15/2022
    Primary completion :
    09/01/2023
    Completion :
    09/01/2023
    PD-L1
    |
    PD-L1 expression
    |
    paclitaxel • docetaxel • SCT200 • finotonlimab (SCT-I10A)
    SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (NCT04146402)
    Phase 3
    Sinocelltech Ltd.
    Unknown status
    Last update posted :
    02/05/2020
    Initiation :
    12/31/2019
    Primary completion :
    01/29/2022
    Completion :
    07/30/2022
    PD-L1
    |
    cisplatin • finotonlimab (SCT-I10A)
    Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma (NCT04146181)
    Phase 2
    Sinocelltech Ltd.
    Unknown status
    Last update posted :
    12/12/2019
    Initiation :
    10/31/2019
    Primary completion :
    06/30/2021
    Completion :
    09/30/2021
    PD-L1
    |
    cisplatin • finotonlimab (SCT-I10A)